Long-Term Effects of Apixaban Confirmed in the Open-Label Extension of AVERROES Trial

被引：0
|
作者：
Chao, Tze-Fan [1 ,2 ,3 ]
Potpara, Tatjana S. [4 ,5 ]
机构：
[1] Taipei Vet Gen Hosp, Div Cardiol, Dept Med, Taipei, Taiwan
[2] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan
[3] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan
[4] Univ Belgrade, Sch Med, Belgrade, Serbia
[5] Clin Ctr Serbia, Cardiol Clin, Belgrade, Serbia
来源：
THROMBOSIS AND HAEMOSTASIS | 2021年 / 121卷 / 04期
关键词：
ATRIAL-FIBRILLATION; WARFARIN; ANTICOAGULATION; DABIGATRAN; TRANSITION; STROKE; DRUG; END;
D O I：
10.1055/a-1367-0184
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：405 / 407
页数：3
相关论文
共 50 条
  • [1] Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES
    Benz, Alexander P.
    Eikelboom, John W.
    Yusuf, Salim
    Hohnloser, Stefan H.
    Kahl, Anja
    Beresh, Heather
    Balasubramanian, Kumar
    Healey, Jeff S.
    Connolly, Stuart J.
    THROMBOSIS AND HAEMOSTASIS, 2021, 121 (04) : 518 - 528
  • [2] Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
    Devinsky, Orrin
    Nabbout, Rima
    Miller, Ian
    Laux, Linda
    Zolnowska, Marta
    Wright, Stephen
    Roberts, Claire
    EPILEPSIA, 2019, 60 (02) : 294 - 302
  • [3] Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial.
    Becker, Michael A.
    Baraf, Herbert S. B.
    Yood, Robert A.
    Dillon, Aileen M.
    Vazquez-Mellado, Janitzia
    Ottery, Faith D.
    Khanna, Dinesh
    Sundy, John S.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S69 - S70
  • [4] LONG-TERM PERAMPANEL USE IN OPEN-LABEL EXTENSION STUDIES
    Rektor, Ivan
    Krauss, Gregory L.
    Inoue, Yushi
    Kaneko, Sunao
    Williams, Betsy
    Patten, Anna
    Bibbiani, Francesco
    Laurenza, Antonio
    Wechsler, Robert T.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A23 - A23
  • [5] Fluoxetine for the treatment of childhood anxiety disorders: Open-label, long-term extension to a controlled trial
    Clark, DB
    Birmaher, B
    Axelson, D
    Monk, K
    Kalas, C
    Ehmann, M
    Bridge, J
    Wood, DS
    Muthen, B
    Brent, D
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2005, 44 (12): : 1263 - 1270
  • [6] An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia
    Murakami, Masato
    Osada, Kenichi
    Ichibayashi, Hisao
    Mizuno, Hiromichi
    Ochiai, Toshimitsu
    Ishida, Mitsuhiro
    Alev, Levent
    Nishioka, Kusuki
    MODERN RHEUMATOLOGY, 2017, 27 (04) : 688 - 695
  • [7] Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial
    McConville, B
    Carrero, L
    Sweitzer, D
    Potter, L
    Chaney, R
    Foster, K
    Sorter, M
    Friedman, L
    Browne, K
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (01) : 75 - 82
  • [8] Long-term effects of troglitazone - Open-label extension studies in type 2 diabetic patients
    Fonseca, V
    Foyt, HL
    Shen, K
    Whitcomb, R
    DIABETES CARE, 2000, 23 (03) : 354 - 359
  • [9] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [10] Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Kwan, Patrick
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Wheless, James
    EPILEPSIA, 2022, 63 (02) : 426 - 439
12345